Nature cancerPub Date : 2026-08-03DOI: 10.1038/s43018-026-01205-3
Sarada Achyutuni, Jian Xu
{"title":"Copper dependency in leukemia metabolism","authors":"Sarada Achyutuni, Jian Xu","doi":"10.1038/s43018-026-01205-3","DOIUrl":"10.1038/s43018-026-01205-3","url":null,"abstract":"Despite their crucial roles in physiology, the contributions of trace metals to cancer fitness and therapy response remain unclear. Combining a CRISPR screen with functional and metabolic studies, recent work identifies copper homeostasis as a key regulator of mitochondrial metabolism and liability in cerebrospinal fluid-infiltrating acute lymphoblastic leukemia cells.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 8","pages":"1-3"},"PeriodicalIF":28.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-29DOI: 10.1038/s43018-026-01224-0
Hao Zheng, Jinming Liu, Qi Cheng, Qianping Zhang, Yaoyao Zhang, Lingyu Jiang, Yan Huang, Wenlei Li, Yanping Zhao, Guo Chen, Fan Yu, Lei Liu, Yanjun Li, Xudong Liao, Lai Xu, Yi Xiao, Zhibo Zheng, Ming Li, Hongyi Wang, Gang Hu, Lei Du, Quan Chen
{"title":"Retraction Note: Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance","authors":"Hao Zheng, Jinming Liu, Qi Cheng, Qianping Zhang, Yaoyao Zhang, Lingyu Jiang, Yan Huang, Wenlei Li, Yanping Zhao, Guo Chen, Fan Yu, Lei Liu, Yanjun Li, Xudong Liao, Lai Xu, Yi Xiao, Zhibo Zheng, Ming Li, Hongyi Wang, Gang Hu, Lei Du, Quan Chen","doi":"10.1038/s43018-026-01224-0","DOIUrl":"10.1038/s43018-026-01224-0","url":null,"abstract":"","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 8","pages":"1323-1323"},"PeriodicalIF":28.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s43018-026-01224-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-28DOI: 10.1038/s43018-026-01204-4
Emily B. Derrick, Paul A. Beavis
{"title":"Iron-ing out ferroptosis-mediated T cell dysfunction in cancer","authors":"Emily B. Derrick, Paul A. Beavis","doi":"10.1038/s43018-026-01204-4","DOIUrl":"10.1038/s43018-026-01204-4","url":null,"abstract":"T cell dysfunction restrains the efficacy of immune checkpoint blockade and CAR-T cell-based cancer therapies. Iron-mediated ferroptosis is now shown to contribute to the dysfunction of endogenous T cells and CAR-T cells, suggesting that inhibition of ferroptosis could improve the anti-tumor activity of CAR-T cells in cancer.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 8","pages":"1163-1164"},"PeriodicalIF":28.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148605499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-21DOI: 10.1038/s43018-026-01208-0
Hongnan Mo, Yuee Teng, Li Cai, Huihui Li, Xinhong Wu, Jing Yao, Yu Wang, Dan Lv, Xuenan Peng, Shuchun Wang, Rongrong Chen, Xin Yi, Qingyao Shang, Youwen He, Ji Liu, Zheng Pang, Tianyu Feng, Fei Ma
{"title":"Dalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial","authors":"Hongnan Mo, Yuee Teng, Li Cai, Huihui Li, Xinhong Wu, Jing Yao, Yu Wang, Dan Lv, Xuenan Peng, Shuchun Wang, Rongrong Chen, Xin Yi, Qingyao Shang, Youwen He, Ji Liu, Zheng Pang, Tianyu Feng, Fei Ma","doi":"10.1038/s43018-026-01208-0","DOIUrl":"10.1038/s43018-026-01208-0","url":null,"abstract":"Visceral crisis in advanced breast cancer (ABC) represents a major challenge. Here we conducted a phase 2 study to evaluate dalpiciclib plus endocrine therapy (ET) in women with HR+/HER2− ABC experiencing visceral crisis. The primary endpoint was the 6-month survival rate; secondary endpoints included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), 3-month treatment failure rate (TFR), duration of disease control (DDC), objective response rate (ORR), disease control rate (DCR) and safety. Among 53 participants, 49 survived beyond 6 months, yielding a 6-month survival rate of 92.5% (95% confidence interval (CI): 81.8–97.9), meeting the primary endpoint. The ORR was 26.4%, DCR was 79.2% and 3-month TFR was 22.6%. The median PFS was 11.2 months (95% CI: 7.6–19.3), DDC was 14.1 months (95% CI: 8.4–21.5) and TTF was 10.2 months (95% CI: 6.4–15.6); the median OS was not reached. The most common grade ≥3 adverse events were neutrophil count decreased (77.4%) and white blood cell count decreased (54.7%). Exploratory analyses indicated that a baseline monocyte-derived cfDNA level below 0.0581 was associated with worse OS (hazard ratio: 4.79, 95% CI: 1.05–45.47, P = 0.0394), indicating a ‘molecular crisis’. These findings support further evaluation of dalpiciclib plus ET in persons with ABC with visceral crisis (ClinicalTrials.gov: NCT05431504 ). In this multicenter, nonrandomized, phase 2 trial, Ma and colleagues report the results of treatment with dalpiciclib plus endocrine therapy in persons with HR+/HER2− advanced breast cancer experiencing visceral crisis.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 8","pages":"1312-1321"},"PeriodicalIF":28.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-17DOI: 10.1038/s43018-026-01214-2
Heathcliff Dorado García
{"title":"Androgen loss contributes to neuroinflammation and promotes brain tumor growth","authors":"Heathcliff Dorado García","doi":"10.1038/s43018-026-01214-2","DOIUrl":"10.1038/s43018-026-01214-2","url":null,"abstract":"","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 7","pages":"1020-1020"},"PeriodicalIF":28.0,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-16DOI: 10.1038/s43018-026-01213-3
Ioanna Pavlaki
{"title":"Leukemic and normal hematopoietic stemness is influenced by transposable elements","authors":"Ioanna Pavlaki","doi":"10.1038/s43018-026-01213-3","DOIUrl":"10.1038/s43018-026-01213-3","url":null,"abstract":"","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 7","pages":"1019-1019"},"PeriodicalIF":28.0,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-15DOI: 10.1038/s43018-026-01200-8
Remi Hatinguais, Stan Verjans, Joana Gomes, Sandra J. van Vliet
{"title":"Immune implications and therapeutic opportunities of tumor glycosylation","authors":"Remi Hatinguais, Stan Verjans, Joana Gomes, Sandra J. van Vliet","doi":"10.1038/s43018-026-01200-8","DOIUrl":"10.1038/s43018-026-01200-8","url":null,"abstract":"Aberrant glycosylation is a nearly universal hallmark of cancer cells. Tumor-associated glycans can reshape cancer cell biology and act as crucial suppressors of anti-tumor immunity. By engaging immune inhibitory receptors or by modifying the function of immune checkpoints, glycans dampen natural immune responses and immunotherapy efficacy. Therefore, glycans serve both as direct targets for anticancer interventions and as adjuvants aimed at potentiating immunotherapy success. In this Review, we provide an overview of tumor glycosylation and its impact on cancer immune surveillance. Finally, we discuss recent therapeutic developments that highlight the potential of glycans as precision cancer medicines. In this Review, van Vliet and colleagues provide an overview of aberrant glycosylation as a hallmark of cancer cells, focusing on its impact for cancer immunity and therapeutic opportunities.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 7","pages":"1031-1046"},"PeriodicalIF":28.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148456604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-15DOI: 10.1038/s43018-026-01196-1
{"title":"A targetable micropeptide reprograms macrophages to suppress T cell anti-tumor immunity","authors":"","doi":"10.1038/s43018-026-01196-1","DOIUrl":"10.1038/s43018-026-01196-1","url":null,"abstract":"We identify UEIS, a micropeptide expressed in tumor-associated macrophages (TAMs), as a suppressor of anti-tumor immunity. In both human cells and mouse models, UEIS dampened cGAS–STING–type I interferon signaling in TAMs by sequestering TBK1 within biomolecular condensates in a negative feedback loop. Targeted disruption of UEIS condensation restored anti-tumor responses and improved the efficacy of immune checkpoint blockade.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 7","pages":"1027-1028"},"PeriodicalIF":28.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148456533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature cancerPub Date : 2026-07-15DOI: 10.1038/s43018-026-01180-9
Animesh Kar, Daniel Herranz
{"title":"A polyadenylation enzyme rewires metabolism to fuel AML","authors":"Animesh Kar, Daniel Herranz","doi":"10.1038/s43018-026-01180-9","DOIUrl":"10.1038/s43018-026-01180-9","url":null,"abstract":"mRNA polyadenylation is a tightly controlled process, but its role in cancer remains poorly understood. A study now shows that the RNA-modifying enzyme poly(A) polymerase α (PAPOLA) is crucial for acute myeloid leukemia generation and progression via an axis that can be effectively targeted therapeutically, offering new hope for patients.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"7 8","pages":"1168-1170"},"PeriodicalIF":28.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148456574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}